NCT05710783: Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. |
|
|
| Completed | 2/3 | 4065 | RoW | AVX-COVID/12, Recombinant NDV Vectored Vaccine for SARS-CoV-2, ChAdOx-1-S[recombinant], AstraZeneca COVID vaccine | Laboratorio Avi-Mex, S.A. de C.V., National Council of Science and Technology, Mexico, Instituto Nacional de Enfermedades Respiratorias | SARS-CoV-2 Infection | 12/22 | 09/23 | | |